EA202191489A1 - Способы лечения миелопролиферативных расстройств - Google Patents

Способы лечения миелопролиферативных расстройств

Info

Publication number
EA202191489A1
EA202191489A1 EA202191489A EA202191489A EA202191489A1 EA 202191489 A1 EA202191489 A1 EA 202191489A1 EA 202191489 A EA202191489 A EA 202191489A EA 202191489 A EA202191489 A EA 202191489A EA 202191489 A1 EA202191489 A1 EA 202191489A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
methods
myeloproliferative disorders
isoxazolo
azepin
Prior art date
Application number
EA202191489A
Other languages
English (en)
Russian (ru)
Inventor
Адриан Сендерович
Майкл Купер
Original Assignee
Констеллейшен Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Констеллейшен Фармасьютикалс, Инк. filed Critical Констеллейшен Фармасьютикалс, Инк.
Publication of EA202191489A1 publication Critical patent/EA202191489A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EA202191489A 2018-11-27 2018-11-27 Способы лечения миелопролиферативных расстройств EA202191489A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2018/062534 WO2020112086A1 (en) 2018-11-27 2018-11-27 Methods of treating myeloproliferative disorders

Publications (1)

Publication Number Publication Date
EA202191489A1 true EA202191489A1 (ru) 2021-09-10

Family

ID=64734125

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191489A EA202191489A1 (ru) 2018-11-27 2018-11-27 Способы лечения миелопролиферативных расстройств

Country Status (8)

Country Link
JP (2) JP7453230B2 (enExample)
KR (2) KR20250004357A (enExample)
AU (1) AU2018451360B2 (enExample)
BR (1) BR112021010134A2 (enExample)
CA (1) CA3120973A1 (enExample)
EA (1) EA202191489A1 (enExample)
SG (1) SG11202105279SA (enExample)
WO (1) WO2020112086A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020112939A1 (en) 2018-11-27 2020-06-04 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
IL300337A (en) * 2020-08-04 2023-04-01 Constellation Pharmaceuticals Inc 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[5,4-E]azepin-4-yl)acetamide for the treatment of thrombocythemia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
LT3157928T (lt) 2014-06-20 2019-05-27 Constellation Pharmaceuticals, Inc. 2-((4s)-6-(4-chlorfenil)-1-metil-4h-benzo[c]iizoksazolo[4,5-e]azepin-4-il)acetamido kristalinės formos

Also Published As

Publication number Publication date
JP2022519425A (ja) 2022-03-24
SG11202105279SA (en) 2021-06-29
CA3120973A1 (en) 2020-06-04
WO2020112086A1 (en) 2020-06-04
AU2018451360A1 (en) 2021-06-10
JP7453230B2 (ja) 2024-03-19
KR102738936B1 (ko) 2024-12-06
KR20250004357A (ko) 2025-01-07
AU2018451360B2 (en) 2022-05-26
JP2024063214A (ja) 2024-05-10
KR20210095904A (ko) 2021-08-03
BR112021010134A2 (pt) 2021-08-24

Similar Documents

Publication Publication Date Title
PH12021551180A1 (en) Methods of treating myeloproliferative disorders
CY1121997T1 (el) Κρυσταλλικες μορφες του 2-((4s)-6-(4-χλωροφαινυλ)-1-μεθυλ-4η-βενζο[c]ισοξαζολo[4,5-ε]αζεπιν-4-υλ)ακεταμιδιου
SA519402217B1 (ar) مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون
EA202191489A1 (ru) Способы лечения миелопролиферативных расстройств
EA201990226A1 (ru) Способы и композиции для лечения миелофиброза
DK3230298T3 (da) 3-substituerede 5-amino-6H-thiazolo[4,5-d]pyrimidin-2,7-dion forbindelser til behandling og forebyggelse af virusinfektion
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
DK3215511T3 (da) Substituerede pyrazolo(1,5-a)pyrimidiner og deres anvendelse i behandlingen af medicinske lidelser
KR20230104752A9 (ko) 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물및 의학적 장애의 치료에서의 그의 용도
WO2015195863A8 (en) Hydrated 2-((4s)-6-(4-chlorophenyl)-1 -methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
MX386415B (es) Uso de (s)-n-(5-((r)-2-(2,5-difluorofenil) pirrolidin-1-il)- pirazolo [1,5-a] pirimidin-3-il) -3-hidroxipirrolidina-1- carboxamida para tratar cánceres pediátricos.
EP3452480A4 (en) SUBSTITUTED PYRROLO [1,2-] TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
DK3509598T3 (da) Ny anvendelse af triazolo(4,5-d)pyrimidinderivater til forebyggelse og behandling af bakteriel infektion
MX2019015212A (es) Compuestos para el tratamiento del sarcoma.
IL287745A (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
EA202090180A1 (ru) Композиции nk1-антагониста и способы лечения депрессии
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
EA201792123A1 (ru) Лечение боли
MX2019015280A (es) Composiciones de estatinas y metodos para su uso en el tratamiento de sinucleinopatias.
EA201992004A1 (ru) Способы предотвращения или лечения офтальмологических заболеваний
EA201892583A1 (ru) Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора
MX2025002392A (es) Formulaciones de dantroleno y metodos de uso de dichas formulaciones
CL2023000362A1 (es) Métodos de tratamiento de la trombocitemia
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
EA201992604A1 (ru) Полинуклеотиды aadc для лечения болезни паркинсона